Directory board

Steering committee

Patricia Ame-Thomas

INSERM U917-MICA
patricia.ame@univ-rennes1.fr

Pierre-François Cartron

Centre de Recherche en Cancérologie Nantes-Angers
Pierre-francois.cartron@inserm.fr

Michel Cherel

Centre de Recherche en Cancérologie Nantes-Angers
michel.cherel@univ-nantes.fr

Nicolas Degauque

INSERM UMR 1064 Center for Research in Transplantation and Immunology 
nicolas.degauque@inserm.fr

Jean-François Fonteneau

Centre de Recherche en Cancérologie Nantes-Angers
jean-francois.fonteneau@univ-nantes.fr

Laetitia Gautreau

Centre de Recherche en Cancérologie Nantes-Angers
laetitia.gautreau@univ-nantes.fr

Fabienne Haspot

INSERM UMR 1064 Center for Research in Transplantation and Immunology 
fabienne.haspot@inserm.fr

Regis Josien

INSERM UMR 1064 Center for Research in Transplantation and Immunology 
regis.josien@inserm.fr

François Lang

Centre de Recherche en Cancérologie Nantes-Angers
francois.lang@univ-nantes.fr

Scientific Committee

Paolo Dellabona

Paolo DellabonaPaolo Dellabona graduated in medicine and obtained a Ph.D. in medical genetics from the University of Torino. He is currently joint-head with Giulia Casorati of the Experimental Immunology Unit and Coordinator of the Program of Cancer Immunology and Immuno-Biotherapy at the San Raffaele Scientific Institute in Milano. His main scientific interest concerns the understanding of the development and anti-tumor functions of CD1-restricted T lymphocytes, with a particular focus on NKT cells, a subset of T lymphocytes displaying innate effector functions.

Barbara Seliger

Barbara SeligerProfessor Dr. Barbara Seliger is the Director of the Institute for Medical Immunology at the Martin-Luther-University Halle-Wittenberg, in Halle, Germany, Director of a FOCIS Center of Excellence, member of the World Immunoscore and SITC biomarker initiatives. In addition she is head of the work group for “Tumor immunology” of the German Society of Immunology. Prof. Seliger’s research team studies the molecular events associated with immune escape of tumors, the role of the tumor microenvironment and immune cell subpopulations for tumor development and therapy resistance. One major goal is to understand the molecular mechanisms, by which tumor cells modulate the immune response in order to escape immune surveillance. This includes immune check point pathways and abnormalities of HLA class I and class II antigens as well as non-classical HLA antigens. Recently, she became interested in the identification, functional characterization and clinical relevance of immune regulatory microRNAs, RNA-binding proteins and their implementation as therapeutic tools and the role of the tumor and immune cell metabolism in shaping anti-tumoral immune response. In addition, she is involved in a number of immunotherapeutic clinical trials. She has published more than 270 papers, is member of the Editorial Board of OncoImmunology, Journal of Translational Medicine, Proteomics – Clinical Proteomics, reviewer of many high impact journals and national as well as international grants and organizer/co-organizer of national and international workshops and symposia. During her scientific life she did win a number of awards including the recent ARF Award of the Qatar Foundation (2014) and the research price of the state Saxonia-Anhalt for the most innovative research project.

Pierre Coulie

Pierre CouliePierre G. Coulie, MD PhD, born in Brussels in 1957, is Full Professor at the Faculty of Medicine of the Université catholique de Louvain, located in Brussels, where he teaches immunology. He worked with Prof. Jacques Van Snick on murine rheumatoid factor and cytokines. In 1988 he joined the group of Prof. Thierry Boon and switched to human immunology. Investigator at the Brussels branch of the Ludwig Institute for Cancer Research from 1989 to 1995, he made important contibutions to the identification of human tumor-specific antigens recognized by T lymphocytes. Pursuing his collaboration with the teams of the Ludwig Institute, he is primarily interested in human anti-tumor immunology in the context of therapeutic vaccination with tumor-specific antigens. His current work is focused on the mechanisms of the tumor regressions that are observed in some vaccinated cancer patients, in order to improve the clinical efficacy of these new and remarkably non-toxic cancer treatments.

Jonathan Bromberg

Jonathan BrombergJonathan Bromberg received his MD and PhD degrees from Harvard University (1983), General Surgery Training at the University of Washington (1988), and Transplant Surgery Training at the University of Pennsylvania (1990). He is currently Professor of Surgery and Microbiology and Immunology, and Chief of the Division of Transplantation, at the University of Maryland School of Medicine in Baltimore, Maryland, USA. His clinical interests are in kidney and pancreas transplantation. His research interests are in the migration and trafficking of T cells to secondary lymphoid organs, with a particular focus on suppressive regulatory T cells and their interaction with specific microdomains in the lymph node which determine T cell fate and tolerance.

Megan Sykes

Megan SykesDr. Sykes joined Columbia University in April, 2010 after spending 19 years at Massachusetts General Hospital/Harvard Medical School, where she was the Harold and Ellen Danser Professor of Surgery and Professor of Medicine (Immunology). Dr. Sykes’ research career, during which she has published 388 papers and book chapters, has been in the areas of hematopoietic cell transplantation, achievement of graft-versus-leukemia effects without GVHD, organ allograft tolerance induction and xenotransplantation. Dr. Sykes has developed novel strategies for achieving graft-versus-tumor effects without graft-versus-host disease following hematopoietic cell transplantation (HCT). She developed an approach that has been evaluated in clinical trials of non-myeloablative haploidentical HCT whose safety and efficacy allowed trials of HCT for the induction of organ allograft tolerance, with the first intentional achievements of this outcome. Dr. Sykes has dissected the tolerance mechanisms and pioneered minimal conditioning approaches for using HCT to achieve allograft and xenograft tolerance and to reverse the autoimmunity of Type 1 diabetes.

Hans-Dieter Volk

Hans-Dieter VolkH.D. Volk borned in 1953. He is Director of the Inst.Med.Immunology, Charité, Director of the Berlin-Brandenburg Center for Regerative Therapies (BCRT) and Deputy Speaker of the Berlin-Brandenburg School for Regenerative Therapies (BSRT) –DFG Graduate School. He published more than 50 patents and is PI or at the steering committees of several collaborative research projects as : Adoptive T cell therapy TR 36 (DFG, 2009),Suppression of undesired immune reaction SFB 650 (DFG, 2013), BioDrIm (EU, 2012), The One Study (EU, 2010), BSRT Graduate School (DFG, 2008), TCR Sequences (IBB, 2010). In 2008, he obtained W3 professorship on Immunology and Regeneration, Charité, HUB.

Marc Bonneville

Marc BonnevilleMarc Bonnevillestarted to work in 1983 on transplantation immunology in Nantes (France), and then switched from 1987 to 1989 to upstream immunological issues dealing with mouse cellular immune responses during his postdoctoral training in S. Tonegawa’s laboratory (MIT, Boston). Since 1990 he has been heading a research group working on human cellular immune responses in various physiopathological contexts, with a main focus on so-called « transitional immunity » mediated by gd and NKT cells on the one hand, and virus-specific conventional T cell responses on the other hand. Together with 5 other scientists, he founded in 1999 a biotech company (Innate Pharma SA) that has been developing new immunotherapeutic approaches targeting innate lymphocytes (gd T and NK cells) in the field of infectiology and oncology. Marc Bonneville has authored around 200 scientific papers and 8 patents. He has received several awards and prizes (Bronze and Silver CNRS medal, Halpern and LNCC prizes, …). He has been involved in more than 20 scientific councils and committees and has been an advisor of the INSERM General Director in the field of immunology and biotherapies from 2000 to 2007. As of October 2013, Marc Bonneville has taken up the position of vice-president in charge of the scientific and medical affairs of Institut Merieux, a company dedicated to the development of diagnostic and therapeutic tools in the fields of infectious diseases, cancer and food safety.